Clinical Trial

Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated November 5, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does Infliximab-dyyb Biosimilar (Remsima) works to treat moderate to severe plaque Psoriasis in adults in reducing disease severity and relapses? What medical problems do participants have when taking Remsima? Participants will: be injected Infliximab Biosimilar Remsima weekly for 4 weeks and then fortnightly till 24 weeks They will be followed for efficacy and safety and lab tests at week 4, 14, 24 and 52.
Trial Details
NCT Number NCT06591273
Lead Sponsor Services Institute of Medical Sciences, Pakistan
Conditions Moderate to Severe Chronic Plaque Psoriasis
Enrollment 104 participants
Start Date 2023-11-06
Primary Completion 2024-11-05 (estimated)
Study Completion 2024-11-05 (estimated)
Updated on ClinicalTrials.gov 2024-09-19